Increasing Treatment Options for Patients with Low-Grade Pseudomyxoma Peritonei

Authors

Shannon Altpeter, University of LynchburgFollow

Specialty

surgical oncology

Advisor

Dr. Mary Walton

Abstract

Pseudomyxoma peritonei (PMP) is the state where the peritoneal lining of the abdominopelvic cavity accumulates with mucin, most often as a result of a primary mucinous appendiceal neoplasm. The incidence has increased to about 1 to 3 cases per million people in a year. Low-grade PMP from a low-grade mucinous appendiceal neoplasm is a smaller population of patients in this already rare disease process. Randomized controlled trials are difficult to conduct, but expert consensus for management and treatment exists. Despite the consensus, controversy and variability in treatment recommendations occur. Cytoreductive surgery and heated intraperitoneal chemotherapy are considered the standard of care. These treatment options have the potential for cure in low-grade PMP, but not in every patient. Alternate and novel treatment options must be explored, including mucolytic therapy, intraperitoneal delivery systems for chemotherapy, and multi-visceral transplantation. A review and dissemination of knowledge are necessary for this disease process to offer patients treatment options that have the potential to increase survival and quality of life.

Recommended Citation

Altpeter S. Increasing Treatment Options for Patients with Low-Grade Pseudomyxoma Peritonei. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2023; 5(1).